



Docket No. 55865 (71965)

1645  
#12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: S. TOJI, et al.

U.S.S.N.: 09/830,706

EXAMINER: N/A

FILED: April 27, 2001

GROUP: N/A

FOR: THIOREDOXIN REDUCTASE II

TECH CENTER 1600/2900

OCT 18 2002

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

\*\*\*\*\*

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date

October 7, 2002

By

Judith A. Herrick

Judith A. Herrick

\*\*\*\*\*

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publication and/or patent shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

**REMARKS**

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X   (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2) within three months of the mailing date of the Search Report issued by the **European Patent Office** (dated                     ) (**COPY ENCLOSED**); or
- (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$240.00**, is included herein; or

— (4) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that the document shown on the attached form PTO-1449 be made of record in this application. Copy of the document (CHECK ONE):

  X   is enclosed herewith; or  
— have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

#### **FEE AUTHORIZATION**

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



\_\_\_\_\_  
Peter F. Corless (Reg. 33,860)  
Edwards & Angell, LLP  
P.O. Box 9169  
Boston, MA 02209  
(617) 439-4444

Customer No. 21874



RECEIVED  
OCT 18 2002

TECH CENTER 1600/2900

Sheet 1 of 1

FORM PTO-1449		DOCKET NO.: 55865 (71965)		SERIAL NO.: 09/830,706			
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): S. TOJI, et al.					
		FILING DATE: APRIL 27, 2001		GROUP NO.: N/A			
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	AA	Sun QA, et al., <u>Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductase</u> , <i>J. Biol Chem</i> :274(35) 24522-24530, 1999;					
	AB	Tamura T, et al., <u>A new selenoprotein from human lung adenocarcinoma cells: Purification, properties, and thioredoxin reductase activity</u> , <i>Proc Natl Acad Sci USA</i> :93(3) 1006-1011, 1996;					
	AC	Gladyshev VN, et al., <u>Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene</u> , <i>Proc Natl Acad Sci USA</i> :93(12) 6146-6151, 1996.					
Examiner:					Date:		